Latest News about ALBO
Recent news which mentions ALBO
Why These Two Biotech Stocks Blasted Higher This Week
January 13, 2023
From Motley Fool
Will 2023 be the year that pharma M&A makes a comeback?
January 12, 2023
From MarketWatch
Cowen & Co. Downgrades Albireo Pharma: Here's What You Need To Know
January 11, 2023
Tickers
ALBO
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 11, 2023
January 11, 2023
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 10, 2023
January 10, 2023
From Benzinga
S&P 500 Gains 0.6%; Albireo Pharma Shares Spike Higher
January 09, 2023
From Benzinga
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
January 09, 2023
From Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
January 09, 2023
From Benzinga
Nasdaq Surges Over 200 Points; Crude Oil Rises 2%
January 09, 2023
From Benzinga
2 Tiny Nasdaq Stocks Making Major Merger Moves Monday
January 09, 2023
From Motley Fool
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 9, 2023
January 09, 2023
From Benzinga
US Stocks Open Higher; Dow Rises 150 Points
January 09, 2023
From Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
January 09, 2023
From Benzinga
Why CinCor Pharma Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket
January 09, 2023
From Benzinga
From InvestorPlace
From MarketWatch
France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline
January 09, 2023
From Benzinga
Have A Look At William Blair's Top Biotech Picks For 2023
December 25, 2022
From Benzinga
Looking Into Albireo Pharma's Return On Capital Employed
December 05, 2022
Tickers
ALBO
From Benzinga
Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday
November 10, 2022
From Benzinga
Why RumbleON Shares Are Trading Higher By Around 28%? Here Are 84 Stocks Moving In Wednesday's Mid-Day Session
November 09, 2022
From Benzinga
Analysts Expect Mirum Pharma's Liver Disease Candidate Might Exceed Rival Product's Penetration
October 25, 2022
From Benzinga
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
